Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
Prospectively Investigate the effectiveness and safety of neoadjuvant Bevacizumab +
chemotherapy (mFOLFOX6) combined with short-course radiotherapy (25Gy/5Fx) for RAS
mutant-type locally advanced rectal cancer